Ligand Pharmaceuticals Inc. (LGND)
| Market Cap | 1.98B |
| Revenue (ttm) | 143.43M |
| Net Income (ttm) | -16.11M |
| Shares Out | 16.08M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | 17.51 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $123.34 |
| Previous Close | $122.28 |
| Change ($) | 1.06 |
| Change (%) | 0.87% |
| Day's Open | 122.01 |
| Day's Range | 121.00 - 126.05 |
| Day's Volume | 310,418 |
| 52-Week Range | 63.37 - 126.72 |
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Fo...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) t...
Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success.
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery p...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Adm...
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations.
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2020 Results - Earnings Call Transcript
Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operati...
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund ta...
It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company's role in the manufacturing of Veklury® (remdesivir), Gilead Sciences' antiviral dr...
Our call of the day comes from a fourth-generation money manager who specializes in finding overlooked smaller companies.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today's virtual Investor Day event its senior management reviewed recent business progress and ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand's ...
HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) fo...
CHENGDU, China--(BUSINESS WIRE)--HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Camb...
President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to appro...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in...
SAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common sto...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to...
Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Ligand Acquisitions, And Other News: The Good, Bad And Ugly Of Biopharma
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology p...
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference. Management will deliver a...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing ...
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. Will it continue?
NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pfen...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Pfenex Inc. (NYSE American: PFNX) today announced the signing of a definitive agreement for Ligand to acquire...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb ...
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q2 2020 Results - Earnings Call Transcript
The company posted strong revenue and earnings growth in Q2 and upped its full-year outlook.
Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating fore...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s C...
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
Ligand Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Ligand Pharmaceuticals Shows Improved Relative Price Performance; Still S...
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodar... [Read more...]
| Industry Biotechnology | IPO Date Nov 18, 1992 |
| CEO John Higgins | Employees 115 |
| Stock Exchange NASDAQ | Ticker Symbol LGND |
Financial Performance
In 2019, LGND's revenue was $120.28 million, a decrease of -52.17% compared to the previous year's $251.45 million. Earnings were $629.30 million, an increase of 339.09%.
Analyst Forecasts
According to 8 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 181.67, which is an increase of 47.29% from the latest price.